Merck KGaA Boosted By Bavencio, Mavenclad And COVID Vaccine Fees
Healthy Q3 For 'Big Three'
The German group's efforts in helping its peers in the industry with their respective COVID-19 vaccines have been rewarded with strong revenue growth while its own newer drugs beat analyst forecasts.
